Skip to Content
MilliporeSigma
  • Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418.

Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418.

The Journal of pharmacology and experimental therapeutics (2014-08-08)
John R Lever, Dennis K Miller, Emily A Fergason-Cantrell, Caroline L Green, Lisa D Watkinson, Terry L Carmack, Susan Z Lever
ABSTRACT

Psychostimulant effects of cocaine are mediated partly by agonist actions at sigma-1 (σ1) receptors. Selective σ1 receptor antagonists attenuate these effects and provide a potential avenue for pharmacotherapy. However, the selective and high affinity σ1 antagonist PD144418 (1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine) has been reported not to inhibit cocaine-induced hyperactivity. To address this apparent paradox, we evaluated aspects of PD144418 binding in vitro, investigated σ1 receptor and dopamine transporter (DAT) occupancy in vivo, and re-examined effects on locomotor activity. PD144418 displayed high affinity for σ1 sites (Ki 0.46 nM) and 3596-fold selectivity over σ2 sites (Ki 1654 nM) in guinea pig brain membranes. No appreciable affinity was noted for serotonin and norepinephrine transporters (Ki >100 μM), and the DAT interaction was weak (Ki 9.0 μM). In vivo, PD144418 bound to central and peripheral σ1 sites in mouse, with an ED50 of 0.22 μmol/kg in whole brain. No DAT occupancy by PD144418 (10.0 μmol/kg) or possible metabolites were observed. At doses that did not affect basal locomotor activity, PD144418 (1, 3.16, and 10 μmol/kg) attenuated cocaine-induced hyperactivity in a dose-dependent manner in mice. There was good correlation (r(2) = 0.88) of hyperactivity reduction with increasing cerebral σ1 receptor occupancy. The behavioral ED50 of 0.79 μmol/kg corresponded to 80% occupancy. Significant σ1 receptor occupancy and the ability to mitigate cocaine's motor stimulatory effects were observed for 16 hours after a single 10.0 μmol/kg dose of PD144418.

MATERIALS
Product Number
Brand
Product Description

Supelco
Cocaine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Haloperidol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Haloperidol, powder
Sigma-Aldrich
1,3-Di-o-tolylguanidine, 99%
Sigma-Aldrich
Cocaine hydrochloride
Supelco
Cocaine hydrochloride solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis
USP
Haloperidol, United States Pharmacopeia (USP) Reference Standard
Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard
Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piperazine, BioUltra, anhydrous, ≥99.0% (T)
Sigma-Aldrich
Piperazine, ReagentPlus®, 99%
Sigma-Aldrich
Cocaine free base
Sigma-Aldrich
Fluoxetine hydrochloride, solid
Sigma-Aldrich
Desipramine hydrochloride, ≥98% (TLC), powder
USP
Desipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Fluoxetine hydrochloride, VETRANAL®, analytical standard
USP
Fluoxetine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Fluoxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material